This HTML5 document contains 168 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n12http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q37158257
rdf:type
wikibase:Item
schema:description
наукова стаття, опублікована в березні 2009 מאמר מדעי 2009年学术文章 2009年の論文 vetenskaplig artikel مقالهٔ علمی artikull shkencor artículo científico publicado en 2009 wetenschappelijk artikel articolo scientifico artigo científico (publicado na 2009) 2009年學術文章 2009년 논문 vitenskapelig artikkel 2009年学术文章 tieteellinen artikkeli บทความทางวิทยาศาสตร์ naučni članak article científic мақолаи илмӣ научни чланак scienca artikolo 2009年學術文章 videnskabelig artikel (udgivet 2009) vitskapeleg artikkel article scientifique publié en 2009 научни чланак գիտական հոդված научна статия articol științific 2009年学术文章 tudományos cikk 2009年学术文章 vedecký článok bài báo khoa học wissenschaftlicher Artikel article scientific мақолаи илмӣ artykuł naukowy artikulong pang-agham 2009年學術文章 2009年学术文章 mokslinis straipsnis سائنسی مضمون επιστημονικό άρθρο teaduslik artikkel scientific article published on 02 March 2009 2009年學術文章 ২০০৯-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ bilimsel makale научная статья artigo científico artigo científico (publicado na 2009) مقالة علمية نشرت في 02 مارس 2009 artículu científicu espublizáu en 2009 2009年學術文章 2009 nî lūn-bûn სამეცნიერო სტატია 2009年學術文章 vědecký článek
p:P577
wds:Q37158257-3F82D674-A76B-4C6F-AD2E-7E55E0B71CD8
wdt:P577
2009-03-02T00:00:00Z
p:P407
wds:Q37158257-C07624DA-AC1D-4C25-928C-E5378ABD0964
wdt:P407
wd:Q1860
p:P2860
wds:Q37158257-0616CE99-4BCF-41D4-975B-5A0F4B03B1C6 wds:Q37158257-643D575B-141F-4DAE-A0BD-CC87E05ECFD2 wds:Q37158257-5268D229-5EF3-4D7D-B07C-0CB1DF767774 wds:Q37158257-5AED8612-CCA5-48DE-9572-6C328E7E8619 wds:Q37158257-232528AD-4A33-40D0-A827-4C0B13632D52 wds:Q37158257-4438CA85-4A2A-472F-965B-834B7E7B7D68 wds:Q37158257-0B6F8FAD-9641-475E-B595-EA32878035D9 wds:Q37158257-1B1C9FB9-B1F4-4F8B-A606-6D572C7930D3 wds:Q37158257-9C78214D-0A3F-407E-963B-45B1B28CFFD7 wds:Q37158257-84117905-E11B-43C5-9FE2-2D7F3F4B1CD3 wds:Q37158257-84E95611-4FF1-4FE2-B2AC-66580819B01A wds:Q37158257-88AB0C26-23F8-45C6-8947-78B0DC33A51C wds:Q37158257-890DBABA-5360-4FF7-9476-3A2FFDEDC512 wds:Q37158257-7279C131-BE4E-46C7-84C5-31E910864F04 wds:Q37158257-7288A689-1814-4D60-B115-152D556CB2E8 wds:Q37158257-72B9E165-CB60-4CDD-B8D5-C41F82D2C873 wds:Q37158257-815948DC-E89D-4099-B321-C99D5E24FD9C wds:Q37158257-655D0BB9-0C28-410A-8882-6D57D8E66A3D wds:Q37158257-FC612A39-DF3B-46F8-9C3E-AF8F4BA21848 wds:Q37158257-EA3DFDB5-490C-4F3B-8FE4-3ED8CFAA3F1D wds:Q37158257-EE5D7552-E34E-4F78-B564-BC3A14FC9C5A wds:Q37158257-D7781F2E-2079-4E00-BBAE-87A12FF554D4 wds:Q37158257-C184D160-52E7-40C6-8DBA-5D95D3999DCC wds:Q37158257-D2761E58-B19E-43A6-A530-C946DBC7CE7D wds:Q37158257-D56F0ADC-68CC-457B-9C8A-518A53B127B3
wdt:P2860
wd:Q81290162 wd:Q33450404 wd:Q57515106 wd:Q68160475 wd:Q33773215 wd:Q36787584 wd:Q78367035 wd:Q47807417 wd:Q80604772 wd:Q45115068 wd:Q47685354 wd:Q40645948 wd:Q46361336 wd:Q77565327 wd:Q28343471 wd:Q33503045 wd:Q53251676 wd:Q80011702 wd:Q34744652 wd:Q46669969 wd:Q54689358 wd:Q51026982 wd:Q34549725 wd:Q34598460 wd:Q81346749
p:P2093
wds:Q37158257-FD53925E-80E8-4E24-B9E9-12BB302CA7B4 wds:Q37158257-DE24D797-16CE-4B87-9E2A-22004749B948 wds:Q37158257-E4D4C4AE-A54E-4CEE-9082-EEBD5850D755 wds:Q37158257-DAD30C4E-6714-4B3B-B6B3-6FB7F522EA59 wds:Q37158257-8A0DDA29-FC30-4395-B31A-9D051AC3824D wds:Q37158257-644E8E2B-2A81-4266-B340-F0644C26D1EC wds:Q37158257-564481D5-AF5B-4070-8696-074F2B3CE313 wds:Q37158257-62E39904-9954-4A3C-97F8-3D7C2F7EF8E7
wdt:P2093
Thomas M Habermann Howard Hochster Stanley Frankel Sandra J Horning Edie Weller Theresa Ryan Natalia Colocci Lijun Zhang
rdfs:label
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.
skos:prefLabel
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study
schema:name
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.
p:P50
wds:Q37158257-BE6C3D23-2F68-4746-B600-8DFDDA107D05 wds:Q37158257-63A4DB47-084F-47C5-A781-B9F38DA90A1E
wdt:P50
wd:Q87831803 wd:Q40235097
p:P1476
wds:Q37158257-601681CC-0E1B-4958-844F-746E3742B2F0
wdt:P1476
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study
p:P304
wds:Q37158257-46CB4FDD-71D2-475B-B950-E3B1A21BB1C5
wdt:P304
1607-1614
p:P31
wds:Q37158257-FDA99A88-B84D-4EDE-BFA8-2A9D9D04A8E2
wdt:P31
wd:Q13442814
p:P921
wds:Q37158257-F3756B00-B649-4714-9131-5942D0913A4A
wdt:P921
wd:Q412323
p:P698
wds:Q37158257-657EF5F4-5395-4FC3-9679-996D9A2FA572
wdtn:P698
n11:19255334
wdt:P698
19255334
p:P1433
wds:Q37158257-1EF15C22-03D6-450A-8194-BCD4CC11BC7F
wdt:P1433
wd:Q400292
p:P433
wds:Q37158257-1027EF04-A1CD-43A8-B034-5555BF113838
p:P478
wds:Q37158257-959A42C3-C110-4F3D-928A-349B80361C0D
wdt:P433
10
wdt:P478
27
p:P356
wds:Q37158257-6B1B86D0-E140-4EDF-B3B7-EEA9296D4AA0
wdtn:P356
n12:JCO.2008.17.1561
wdt:P356
10.1200/JCO.2008.17.1561
p:P5875
wds:Q37158257-F900B2B6-2D89-49A8-8695-18ABC8D7072C
wdt:P5875
24171695
p:P932
wds:Q37158257-1A8BCE6D-7C6D-4D78-A4C9-F47E156A5BA0
wdt:P932
2668968